munkle
Diamond Member
- Dec 18, 2012
- 5,199
- 8,921
- 2,130
How many people died in the "it's horse dewormer!" campaign of vicious lies, intended to keep people dying so the vaxes could get approved under Emergency Use Authorization?
"Another large randomised control study on ivermectin efficacy for preventing and treating COVID-19 has been released to the public ahead of publication in an academic journal. But unlike negative results trials, there has not been a big international splash across the mainstream media coordinated by a large publicity agency such as Bell Pottinger. Why? Because the results are undeniably positive, showing the efficacy of ivermectin in reducing infection after exposure by 72%, documented in a press release on Jan 5 2023(1).
This is the best quality RCT we have yet seen published on ivermectin. It is called the SAIVE Trial (NCT 05305560)(2) and is part of MedinCell’s research supporting their development of a novel slow-release form of ivermectin. Although sparse results have been released so far, the quality of the study is apparent. A total of 399 unvaccinated participants completed the study as per the protocol. The number intended for treatment is not available yet, but I anticipate that the only difference would be that the ITT number for the control group may have been 200. Those participants who received daily oral ivermectin showed a 72% reduction in COVID-19 infection compared to the control group...."
All studies on Ivermectin as treatment for COVID: 62% to 82% improvement including prevention of death. Adopted in over 20 countries.
Ivermectin efficacy finally proven in ‘gold-standard’ RCT – Prof Colleen Aldous
A RCT on Ivermectin efficacy for preventing and treating COVID-19 has been released, as discussed in this article by Prof Colleen Aldous.
www.biznews.com
Large, well-designed randomised control study shows Ivermectin efficacy in preventing and treating COVID-19
By Colleen Aldous, Phillip Oldfield"Another large randomised control study on ivermectin efficacy for preventing and treating COVID-19 has been released to the public ahead of publication in an academic journal. But unlike negative results trials, there has not been a big international splash across the mainstream media coordinated by a large publicity agency such as Bell Pottinger. Why? Because the results are undeniably positive, showing the efficacy of ivermectin in reducing infection after exposure by 72%, documented in a press release on Jan 5 2023(1).
This is the best quality RCT we have yet seen published on ivermectin. It is called the SAIVE Trial (NCT 05305560)(2) and is part of MedinCell’s research supporting their development of a novel slow-release form of ivermectin. Although sparse results have been released so far, the quality of the study is apparent. A total of 399 unvaccinated participants completed the study as per the protocol. The number intended for treatment is not available yet, but I anticipate that the only difference would be that the ITT number for the control group may have been 200. Those participants who received daily oral ivermectin showed a 72% reduction in COVID-19 infection compared to the control group...."
All studies on Ivermectin as treatment for COVID: 62% to 82% improvement including prevention of death. Adopted in over 20 countries.
Last edited: